Skip to main content

Table 2 Factors associated with therapeutic option in patients with severe COVID-19

From: Effects of early corticosteroid use in patients with severe coronavirus disease 2019

 

Early use group (n = 12)

Late use group (n = 10)

p-value

Combination therapy

 Steroid

7/12 (58.3%)

8/10 (80.0%)

0.162

 Steroid + Convalescent plasma

5/12 (41.7%)

1/10 (10.0%)

 Steroid + Remdesivir

0

1/10 (10.0%)

Steroid-related factor

 Time from symptom to steroid use

9.75 ± 3.64

15.70 ± 6.00

0.010

 Time from diagnosis to steroid use

3.00 (2.00–7.00)

12.5 (11.00–14.25)

< 0.001

 Time from hospitalization to steroid use

3.33 ± 3.45

10.00 ± 4.83

0.001

 Initial dosea, mg/kg/day

0.81 (0.50–1.00)

1.00 (0.76–.1.00)

0.456

 Duration, days

14.00 ± 5.00

18.50 ± 14.76

0.380

 Total dosea, mg

521.6 ± 246.38

667.50 ± 606.76

0.490

Score on ordinal scale at steroid start

  

0.035

 O2 with nasal prong

1/8 (12.5%)

0

 

 High flow nasal cannula

7/8 (87.5%)

2/5 (40%)

 Invasive ventilation

0

3/5 (60%)

  1. COVID-19, coronavirus disease 2019
  2. Continuous variables were examined for normality by Kolmogorov-Smirnov test. Continuous variables with normal distribution are shown mean ± standard deviation (SD). Group comparisons were performed using independent two-sample t-test. Continuous non-normal distribution variables are shown as the median interquartile range, and Mann-Whitney U tests were used to compare the differences between groups. Categorical variables are shown as numbers (percentages). Chi-squared tests and Fisher’s exact test were used to compare categorical data in different groups
  3. aDose of corticosteroid was calculated based on methylprednisolone